237 related articles for article (PubMed ID: 22633269)
21. Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma.
Li C; Zhang W; Zhang R; Zhang L; Wu P; Zhang F
Eur J Cancer; 2010 Sep; 46(13):2513-21. PubMed ID: 20663659
[TBL] [Abstract][Full Text] [Related]
22. [Inhibitory effects of human AFP-derived peptide-pulsed dendritic cells on mouse hepatocellular carcinoma].
Pang XH; Chen MS; Jia WH; Zhou XX
Ai Zheng; 2008 Dec; 27(12):1233-8. PubMed ID: 19079985
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of short-term response of high intensity focused ultrasound ablation for primary hepatic carcinoma: utility of contrast-enhanced MRI and diffusion-weighted imaging.
Zhang Y; Zhao J; Guo D; Zhong W; Ran L
Eur J Radiol; 2011 Sep; 79(3):347-52. PubMed ID: 20638211
[TBL] [Abstract][Full Text] [Related]
24. Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits.
Wissniowski TT; Hänsler J; Neureiter D; Frieser M; Schaber S; Esslinger B; Voll R; Strobel D; Hahn EG; Schuppan D
Cancer Res; 2003 Oct; 63(19):6496-500. PubMed ID: 14559842
[TBL] [Abstract][Full Text] [Related]
25. [Therapeutic effects of B and T lymphocyte attenuator extracellular domain and heat shock protein 70 antigen peptide on cervical cancer in mouse model].
Han LF; Qiu WM; Hu C; Wang L; Yao HX; Xiong SY; Meng M; Fang Y; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):603-8. PubMed ID: 21029617
[TBL] [Abstract][Full Text] [Related]
26. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
27. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.
Bai F; Niu Z; Tian H; Li S; Lv Z; Zhang T; Ren G; Li D
Immunol Lett; 2014; 159(1-2):36-46. PubMed ID: 24613899
[TBL] [Abstract][Full Text] [Related]
28. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
29. Regional treatment of hepatic micrometastasis by adenovirus vector-mediated delivery of interleukin-2 and interleukin-12 cDNAs to the hepatic parenchyma.
Hirschowitz EA; Naama HA; Evoy D; Lieberman MD; Daly J; Crystal RG
Cancer Gene Ther; 1999; 6(6):491-8. PubMed ID: 10608345
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
Gabrilovich DI; Ciernik IF; Carbone DP
Cell Immunol; 1996 May; 170(1):101-10. PubMed ID: 8665590
[TBL] [Abstract][Full Text] [Related]
31. Suppression of hepatocellular carcinoma growth via oral immune regulation towards tumor-associated antigens is associated with increased NKT and CD8+ lymphocytes.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Oncology; 2004; 66(4):323-30. PubMed ID: 15218301
[TBL] [Abstract][Full Text] [Related]
32. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
33. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Bristol JA; Schlom J; Abrams SI
Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
[TBL] [Abstract][Full Text] [Related]
34. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
36. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma.
Tang L; Hu HD; Hu P; Lan YH; Peng ML; Chen M; Ren H
Gene Ther; 2007 Aug; 14(16):1226-34. PubMed ID: 17597794
[TBL] [Abstract][Full Text] [Related]
37. [Experimental and clinical research of cytolytic T lymphocytes specific for hepatocellular carcinoma].
Shen F; Wang H; Xie T
Zhonghua Wai Ke Za Zhi; 1997 Feb; 35(2):95-9. PubMed ID: 10374486
[TBL] [Abstract][Full Text] [Related]
38. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
[TBL] [Abstract][Full Text] [Related]
39. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
40. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses.
Zerbini A; Pilli M; Penna A; Pelosi G; Schianchi C; Molinari A; Schivazappa S; Zibera C; Fagnoni FF; Ferrari C; Missale G
Cancer Res; 2006 Jan; 66(2):1139-46. PubMed ID: 16424051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
